PHAXIAM Therapeutics S.A. Logo

PHAXIAM Therapeutics S.A.

PHXM

(1.8)
Stock Price

3,10 USD

-14.01% ROA

-16.28% ROE

-17.91x PER

Market Cap.

18.102.852,99 USD

9.25% DER

0% Yield

0% NPM

PHAXIAM Therapeutics S.A. Stock Analysis

PHAXIAM Therapeutics S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

PHAXIAM Therapeutics S.A. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.

2 ROE

The stock's ROE falls within an average range (3.39%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (1.74%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

4 DER

The stock maintains a fair debt to equity ratio (58%), indicating a reasonable balance between the money it owes and the ownership it possesses.

5 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

6 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

PHAXIAM Therapeutics S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

PHAXIAM Therapeutics S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

PHAXIAM Therapeutics S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

PHAXIAM Therapeutics S.A. Revenue
Year Revenue Growth
2012 1.837.876
2013 1.802.262 -1.98%
2014 4.368.902 58.75%
2015 10.776.000 59.46%
2016 19.719.000 45.35%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

PHAXIAM Therapeutics S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2012 1.622.695
2013 2.502.789 35.16%
2014 2.243.971 -11.53%
2015 10.776.000 79.18%
2016 19.719.000 45.35%
2017 25.463.000 22.56%
2018 33.468.000 23.92%
2019 52.193.000 35.88%
2020 57.580.000 9.36%
2021 45.100.000 -27.67%
2022 19.907.000 -126.55%
2023 13.300.000 -49.68%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

PHAXIAM Therapeutics S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 3.296.250
2013 3.548.519 7.11%
2014 4.361.181 18.63%
2015 7.616.000 42.74%
2016 6.660.000 -14.35%
2017 8.791.000 24.24%
2018 14.600.000 39.79%
2019 17.164.000 14.94%
2020 14.970.000 -14.66%
2021 15.101.000 0.87%
2022 13.887.000 -8.74%
2023 11.844.000 -17.25%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

PHAXIAM Therapeutics S.A. EBITDA
Year EBITDA Growth
2012 -1.865.207
2013 -8.019.475 76.74%
2014 -8.737.806 8.22%
2015 -15.247.000 42.69%
2016 -21.473.000 28.99%
2017 -30.350.000 29.25%
2018 -37.416.000 18.88%
2019 -61.127.000 38.79%
2020 -67.943.000 10.03%
2021 -47.455.000 -43.17%
2022 -22.694.000 -109.11%
2023 -21.944.000 -3.42%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

PHAXIAM Therapeutics S.A. Gross Profit
Year Gross Profit Growth
2012 0
2013 -1.022.937 100%
2014 0 0%
2015 0 0%
2016 0 0%
2017 -25.463.000 100%
2018 -33.468.000 23.92%
2019 -52.193.000 35.88%
2020 -57.580.000 9.36%
2021 -5.377.000 -970.86%
2022 -2.908.000 -84.9%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

PHAXIAM Therapeutics S.A. Net Profit
Year Net Profit Growth
2012 -2.172.035
2013 -8.144.721 73.33%
2014 -8.860.036 8.07%
2015 -15.013.000 40.98%
2016 -21.913.000 31.49%
2017 -33.530.000 34.65%
2018 -38.224.000 12.28%
2019 -62.659.000 39%
2020 -73.300.000 14.52%
2021 -53.797.000 -36.25%
2022 -227.000 -23599.12%
2023 -22.760.000 99%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

PHAXIAM Therapeutics S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 -17 100%
2014 -2 -1600%
2015 -2 50%
2016 -3 0%
2017 -2 -100%
2018 -2 50%
2019 -3 33.33%
2020 -4 0%
2021 -2 -50%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

PHAXIAM Therapeutics S.A. Free Cashflow
Year Free Cashflow Growth
2012 568.900
2013 -6.900.632 108.24%
2014 -7.659.971 9.91%
2015 -14.847.000 48.41%
2016 -19.365.000 23.33%
2017 -26.391.000 26.62%
2018 -53.495.000 50.67%
2019 -63.443.000 15.68%
2020 -52.861.000 -20.02%
2021 -57.068.000 7.37%
2022 -31.849.000 -79.18%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

PHAXIAM Therapeutics S.A. Operating Cashflow
Year Operating Cashflow Growth
2012 621.402
2013 -6.473.233 109.6%
2014 -7.238.532 10.57%
2015 -14.578.000 50.35%
2016 -17.614.000 17.24%
2017 -24.702.000 28.69%
2018 -39.270.000 37.1%
2019 -43.310.000 9.33%
2020 -51.720.000 16.26%
2021 -56.770.000 8.9%
2022 -31.764.000 -78.72%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

PHAXIAM Therapeutics S.A. Capital Expenditure
Year Capital Expenditure Growth
2012 52.502
2013 427.399 87.72%
2014 421.439 -1.41%
2015 269.000 -56.67%
2016 1.751.000 84.64%
2017 1.689.000 -3.67%
2018 14.225.000 88.13%
2019 20.133.000 29.34%
2020 1.141.000 -1664.5%
2021 298.000 -282.89%
2022 85.000 -250.59%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

PHAXIAM Therapeutics S.A. Equity
Year Equity Growth
2012 -4.026.991
2013 13.586.635 129.64%
2014 35.824.303 62.07%
2015 47.132.000 23.99%
2016 35.638.000 -32.25%
2017 181.420.000 80.36%
2018 145.603.000 -24.6%
2019 85.559.000 -70.18%
2020 26.539.000 -222.39%
2021 22.845.000 -16.17%
2022 23.486.000 2.73%
2023 36.632.000 35.89%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

PHAXIAM Therapeutics S.A. Assets
Year Assets Growth
2012 10.143.884
2013 17.948.960 43.48%
2014 40.606.639 55.8%
2015 53.004.000 23.39%
2016 44.967.000 -17.87%
2017 195.261.000 76.97%
2018 167.840.000 -16.34%
2019 118.546.000 -41.58%
2020 80.402.000 -47.44%
2021 66.768.000 -20.42%
2022 45.811.000 -45.75%
2023 65.531.000 30.09%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

PHAXIAM Therapeutics S.A. Liabilities
Year Liabilities Growth
2012 14.170.875
2013 4.362.325 -224.85%
2014 4.782.336 8.78%
2015 5.872.000 18.56%
2016 9.329.000 37.06%
2017 13.841.000 32.6%
2018 22.237.000 37.76%
2019 32.987.000 32.59%
2020 53.863.000 38.76%
2021 43.923.000 -22.63%
2022 22.325.000 -96.74%
2023 28.899.000 22.75%

PHAXIAM Therapeutics S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.16
Price to Earning Ratio
-17.91x
Price To Sales Ratio
0x
POCF Ratio
-7.9
PFCF Ratio
-1.62
Price to Book Ratio
2.39
EV to Sales
0
EV Over EBITDA
0.94
EV to Operating CashFlow
0.33
EV to FreeCashFlow
0.33
Earnings Yield
-0.06
FreeCashFlow Yield
-0.62
Market Cap
0,02 Bil.
Enterprise Value
0,00 Bil.
Graham Number
2.05
Graham NetNet
0.01

Income Statement Metrics

Net Income per Share
-0.16
Income Quality
-13.94
ROE
-0.16
Return On Assets
-0.07
Return On Capital Employed
-0.18
Net Income per EBT
0.6
EBT Per Ebit
0.94
Ebit per Revenue
0
Effective Tax Rate
0.39

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.36
Free CashFlow per Share
-0.36
Capex to Operating CashFlow
0.01
Capex to Revenue
0
Capex to Depreciation
-0.05
Return on Invested Capital
-0.12
Return on Tangible Assets
-0.14
Days Sales Outstanding
0
Days Payables Outstanding
949.39
Days of Inventory on Hand
357.56
Receivables Turnover
0
Payables Turnover
0.38
Inventory Turnover
1.02
Capex per Share
-0

Balance Sheet

Cash per Share
0,81
Book Value per Share
1,18
Tangible Book Value per Share
0.19
Shareholders Equity per Share
1.18
Interest Debt per Share
0.15
Debt to Equity
0.09
Debt to Assets
0.05
Net Debt to EBITDA
5.53
Current Ratio
1.78
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.09
Working Capital
0,01 Bil.
Intangibles to Total Assets
0.47
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
1450500
Debt to Market Cap
0.19

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

PHAXIAM Therapeutics S.A. Dividends
Year Dividends Growth

PHAXIAM Therapeutics S.A. Profile

About PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

CEO
Mr. Eric Soyer Ph.D.
Employee
49
Address
60 Avenue Rockefeller
Lyon, 69008

PHAXIAM Therapeutics S.A. Executives & BODs

PHAXIAM Therapeutics S.A. Executives & BODs
# Name Age
1 Mr. Thibaut du Fayet
Chief Executive Officer
70
2 Ms. Frederique Vieville
Chief Regulatory Officer
70
3 Naomi Eichenbaum
Director Investor Relations
70
4 Ms. Anne-Cécile Fumey
Vice President of Human Resources
70
5 Dr. Pascal Birman M.D.
Chief Medical Officer
70
6 Dr. Jérôme Bailly Pharm.D.
Deputy Chief Executive Officer, Deputy GM, Chief Quality Officer & Qualified Person
70
7 Ms. Karine Charton Ph.D.
Chief Business Officer
70
8 Ms. Céline Breda
Chief Technology Officer
70
9 Ms. Cindy Fevre
Chief Scientific Officer
70
10 Mr. Eric Soyer Ph.D.
Deputy Chief Executive Officer, Deputy GM, Chief Financial Officer & Chief Operating Officer
70

PHAXIAM Therapeutics S.A. Competitors